<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400335</url>
  </required_header>
  <id_info>
    <org_study_id>TDC106222</org_study_id>
    <nct_id>NCT00400335</nct_id>
  </id_info>
  <brief_title>Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride</brief_title>
  <official_title>An Open Label Study to Evaluate the Impact of Novel Fixed-dose Testosterone/Dutasteride Combinations on the Relative Bioavailability of the Individual Dutasteride and Testosterone Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of testosterone and dutasteride is intended for use in hypogonadal men. This
      study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone
      administered with and without dutasteride
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lab tests for relative bioavailability of testosterone and dutasteride,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety lab tests of various testosterone/dutasteride formulations,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab tests for additional pharmacokinetic parameters for testosterone &amp; dutasteride,</measure>
    <time_frame>days 1, 2, 3, 19, 20, 21 &amp; 26-31.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Hypogonadism, Male</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanomilled testosterone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>commercially available dutasteride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanomilled dutasteride</intervention_name>
    <other_name>commercially available dutasteride</other_name>
    <other_name>Nanomilled testosterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Are healthy.

          -  Have a BMI within range of 19-32 kg/m2.

          -  Have not taken dutasteride for one year, or finasteride for the past 3 months.

          -  Have a screening PSA &lt; 2.0ng/mL.

        Exclusion criteria:

          -  Have had or have breast or prostate cancer, sleep apnea, psychiatric illness, or any
             other clinically significant current condition.

          -  Have a trigliceride level =500mg/dL.

          -  Have abnormal thyroid or hormone levels.

          -  Would donate more than 500 ML of blood over a 2 month period.

          -  Physician does not think it is a good idea for you to participate in the trial.

          -  Are unwilling to abstain from alcohol during the study.

          -  Have a positive urine drug screen test.

          -  Plan to change your smoking habits during the course of the trial.

          -  Have Hepatitis C, Hepatitis B, or HIV.

          -  Have a lab or ECG abnormality.

          -  Have high or low blood pressure.

          -  Have used of any investigational drug or device during the study or within 30 days
             prior to 1st dosing of study medication.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Testosterone</keyword>
  <keyword>Men</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Dutasteride</keyword>
  <keyword>DHT</keyword>
  <keyword>Androgen deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

